News
Alembic Pharmaceuticals Q3 FY23 revenue up 19% to Rs. 1,509 Cr
Net sales for 9M FY23 up 9% to Rs. 4,246 crore and net profit for 9M FY23 at Rs. 189 crore
- By IPP Bureau
| February 07, 2023
Alembic Pharmaceuticals Limited Q3 FY23 net sales for the quarter was up 19% to Rs.1509 crore whereas net profit for the quarter at Rs. 122 crore.
Net sales for 9M FY23 up 9% to Rs. 4,246 crore and net profit for 9M FY23 at Rs. 189 crore.
Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited said, “The company witnessed topline growth across all the verticals. In particular, the API business outperformed with a 65% growth during the quarter.”
India Formulations Business grew at 12% to Rs. 545 crore in the quarter reflecting performance better than the industry – both in Specialty and Acute segments. Alembic’s specialty segment grew 14% compared to the industry specialty growth of 10% (as per IQVIA)
Growth in the specialty segment was driven by therapies like Gynecology, Anti-Diabetic & Ophthalmology. Alembic Acute business grew by 21% vs representative Industry growth of 11% (as per IQVIA).
On the International Business front, US Generics grew 10% to Rs. 432 crore in the quarter and Ex-US International Formulations grew 7% to Rs. 206 crore in the quarter. API business of the company grew 65% at Rs. 326 crore in the quarter.
9 ANDA approvals received during the quarter; 178 Cumulative ANDA approvals. 4 ANDA filings during the quarter; Cumulative ANDA filings at 246. 129 cumulative DMF Filings.
_256_275.jpg)
.jpg)
